Glycerol Monolaurate, an Analogue to a Factor Secreted by Lactobacillus, Is Virucidal against Enveloped Viruses, Including HIV-1

This article is for informational purposes only and is not medical advice. Full disclaimer →

In one sentence: In laboratory testing, a food-grade compound inactivates HIV-1 virions before they can enter cells — a mechanism that blocks the step between receptor binding and coreceptor engagement.

Welch JL, Xiang J, et al. · mBio (2020)

PubMed 32371599 · DOI · PMC full text

Why this paper matters

The paper establishes a direct virucidal mechanism for GML that is distinct from its previously documented immunomodulatory activity, resolving a gap in how the compound protected against SIV transmission in the 2009 macaque study. The structural analogy to reutericyclin — a metabolite secreted by vaginal Lactobacillus species — offers one molecular hypothesis for why Lactobacillus-dominated microbiomes are epidemiologically associated with reduced HIV-1 acquisition risk, though this bridge between the in vitro finding and the epidemiological observation remains untested. Any translational implications for topical prevention depend on concentration achievability at mucosal surfaces, activity against the CCR5-tropic strains that dominate sexual HIV transmission, and clinical safety — none of which this in vitro paper addresses.

Background

Glycerol monolaurate (GML) is a fatty acid monoglyceride derived from glycerol and lauric acid, already FDA-recognized as Generally Recognized as Safe (GRAS) and widely used in food and cosmetics. Previous research had shown GML possesses broad antibacterial properties and immunoregulatory effects, and a 2009 Nature study demonstrated that topical vaginal GML prevented SIV infection in rhesus macaques — primarily by blocking the host inflammatory signaling that recruits CD4+ T cells to the infection site. However, the question of whether GML could also act as a direct virucidal agent, and precisely how, remained poorly characterized.

A 2020 mBio paper by Schlievert, Strandberg, and colleagues provides the first detailed mechanistic dissection of how GML directly inhibits HIV-1 at the molecular entry level: it acts post-CD4 binding but pre-coreceptor engagement. The work also links GML to reutericyclin, a structurally analogous compound secreted by Lactobacillus reuteri and Enterococcus faecalis, offering a molecular explanation for why Lactobacillus-dominated vaginal microbiomes are epidemiologically associated with reduced HIV-1 transmission. Separately, a 2024 observational cohort study in Italy found that higher serum monolaurin levels were associated with significantly lower COVID-19 risk, extending the compound's relevance beyond STI prevention.

The Mechanism: How GML Jams HIV-1's Door Key

HIV-1 needs two handshakes to enter a cell — GML lets the first happen but permanently blocks the second.

GML reduced HIV-1 surface binding by only 35% at 40 μg/ml, yet completely blocked intracellular viral entry as measured by trypsin-strip assays.^[1] In binding assays at 4°C, 40 μg/ml GML (a noncytotoxic concentration) caused only a modest 35% reduction in HIV-1 p24 detected on cell surfaces. However, in entry assays where cells with pre-bound virus were warmed to 37°C and then treated with trypsin to remove surface-associated virus, GML-treated cells showed essentially zero intracellular p24. Critically, total virus (surface plus intracellular) was not dramatically reduced — the primary antiviral effect is on the entry step itself, not on initial binding.

GML does not interfere with HIV-1 gp120 binding to the CD4 receptor, demonstrated by a cell-cell fusion assay showing no significant reduction in fusion between gp120-expressing and CD4-expressing cells.^[1] Red fluorescence-labeled HL2/3 cells (expressing gp120) were co-incubated with green fluorescence-labeled TZM-bl cells (expressing CD4) in the presence of 40 μg/ml GML. Flow cytometry showed no significant reduction in double-positive (fused) cells compared to controls, proving GML allows the initial CD4-gp120 interaction to proceed normally. This constrains GML's mechanism to steps downstream of initial receptor engagement.

A soluble CD4 pre-triggering experiment directly confirmed GML acts at the post-CD4-binding coreceptor step: HIV-1 pre-exposed to sCD4 to induce gp120 conformational changes still showed significantly impaired entry when GML was present.^[1] HIV-1 was first exposed to soluble CD4 (sCD4) to artificially trigger the conformational changes in gp120 that CD4 binding normally induces. This virus was then spinoculated onto HOS CXCR4+/CD4- cells — cells that express the CXCR4 coreceptor but not CD4. GML still significantly reduced entry onto these cells. Because CD4 was bypassed by sCD4 pre-treatment and the target cells lacked CD4, this experiment directly demonstrates that GML's block occurs at the coreceptor engagement step after the CD4-induced conformational change has already occurred.

When the CXCR4 inhibitor AMD3100 was combined with GML, there was no additional inhibition of HIV-1 beyond AMD3100 alone, pinpointing GML's action to the coreceptor binding step.^[1] TZM-bl cells were pretreated with the CXCR4 antagonist AMD3100 for 1 hour before HIV-1 infection, with GML added at inoculation. The lack of additive or synergistic inhibition indicates GML and AMD3100 target the same step — coreceptor engagement. Since GML doesn't block CD4 binding but does overlap with coreceptor blockade, its action maps precisely to the conformational changes in gp120 required after CD4 binding but before CXCR4 docking.

HIV-1 pre-exposed to GML for 30 minutes and then purified free of residual GML still showed significantly impaired infectivity and entry — but not binding — proving the damage to the virion is permanent.^[1] HIV-1 virions were incubated with GML for 30 minutes at 37°C, then GML was removed by centrifugal filtration (100K Centriprep). The treated but GML-free virus retained reduced infectivity and impaired entry, yet binding to cells was not significantly altered. This proves GML acts directly on the virus particle, causing lasting structural changes to the virion rather than transiently blocking host cell receptors.

GML only works when present at the moment of viral inoculation: cells pre-treated with GML and washed before infection showed no inhibition, and GML added 24 hours post-infection also showed no inhibition at noncytotoxic concentrations.^[1] This timing constraint is mechanistically critical. GML must physically contact the virus or the cell-virus interface at the moment of exposure to block entry. It does not prime cells against future infection, and once HIV-1 has successfully entered a cell, GML cannot reverse or curtail replication. This defines GML strictly as a prophylactic virucidal agent, not a therapeutic one, with direct implications for any clinical microbicide formulation.

Envelope Required: The Viral Passport GML Shreds

If a virus has a lipid envelope, GML can attack it. No envelope? GML is powerless.

GML inhibited all four enveloped viruses tested — HIV-1, mumps virus, yellow fever virus, and Zika virus — but had zero effect on non-enveloped enterovirus 68 and adenovirus type 5.^[1] IC50 values for GML against enveloped viruses were: mumps virus 31 μg/ml, yellow fever virus 45 μg/ml, and Zika virus 59 μg/ml. In contrast, enterovirus 68 (non-enveloped RNA virus) and adenovirus type 5 (non-enveloped DNA virus) showed no inhibition at any tested concentration. This envelope-dependent selectivity strongly supports a mechanism involving direct interaction with the viral lipid bilayer.

Hepatitis A virus provided a natural experiment: GML inhibited the enveloped (light) form of HAV but had no effect on the non-enveloped (heavy) form of the same virus.^[1] HAV exists in two forms — enveloped particles that float near the top of cesium chloride gradients and non-enveloped particles that sediment to the bottom. After isopycnic separation, GML inhibited only the enveloped fraction. This internal control within a single virus species confirms the lipid envelope is the necessary target for GML's antiviral activity, ruling out protein-only or capsid-based mechanisms.

The Lactobacillus Connection: Your Microbiome's Secret Weapon

The bacteria protecting women from HIV may do it partly by making their own version of a food-grade antiviral.

Reutericyclin, a GML structural analogue secreted by Lactobacillus reuteri and Enterococcus faecalis, inhibited HIV-1 infection by 40–50% when HPLC-purified and tested independently.^[1] The researchers used HPLC-purified reutericyclin (from ChemFaces) to eliminate confounding metabolites from bacterial culture. At noncytotoxic concentrations, purified reutericyclin reduced HIV-1 infection in TZM-bl cells by 40–50% as measured by luciferase reporter activity. Crude conditioned media from both reutericyclin-producing bacteria (E. faecalis and L. reuteri) showed even greater inhibition, suggesting additional antiviral metabolites work alongside reutericyclin.

Conditioned media from non-reutericyclin-producing Lactobacillus plantarum also reduced HIV-1 infection, though significantly less than reutericyclin-producing strains, revealing multiple protective mechanisms.^{[1, 6]} This control experiment showed Lactobacillus species produce multiple HIV-1 inhibitory factors beyond reutericyclin. The statistically significant difference between reutericyclin-producing and non-producing strain supernatants confirms reutericyclin as a distinct antiviral contributor. Consistent with this, a 2017 ex vivo study found vaginal Lactobacillus strains inhibit HIV-1 through acidification, specific lactic acid isomers, direct virucidal activity, and physical adsorption of virions — a multi-mechanism defense network.

From Monkeys to Microbicides: The Translational Path

GML already prevented SIV infection in macaques — now we know it works through two distinct mechanisms simultaneously.

In a landmark 2009 Nature study, topical vaginal GML prevented acute and systemic SIV infection in rhesus macaques despite repeated high-dose intravaginal challenge, acting by blocking the host inflammatory response that recruits target cells.^{[2, 3]} Li et al. (Nature 2009; 458:1034–1038) identified a mucosal signaling system involving MIP-3α, plasmacytoid dendritic cells, and CCR5+ cell-attracting chemokines that recruits CD4+ T cells to support viral expansion in the endocervix. GML inhibits this cascade, blocking the innate and inflammatory responses that make the tissue permissive to SIV. This immunomodulatory mechanism is distinct from the direct virucidal entry-blocking mechanism described by Schlievert et al. 2020, suggesting GML operates through complementary protective pathways simultaneously.

A 2015 PLOS ONE follow-up confirmed GML protected against repeat high-dose vaginal SIV challenges and did not disrupt the normal Lactobacillus vaginal microbiota or induce inflammation.^[4] This study demonstrated protection across multiple viral challenges, maintained epithelial integrity during long-term use, and preserved normal vaginal Lactobacillus populations. This safety and microbiome-compatibility profile distinguishes GML from earlier failed microbicide candidates like nonoxynol-9, which disrupted epithelial barriers and paradoxically increased infection risk. The study also identified adherence-independent daily delivery as feasible.

Beyond HIV: A Broad-Spectrum Antiviral Platform

The same compound that fights HIV also works against African swine fever, fish herpesviruses, and possibly COVID-19.

GML inhibits wild-type African Swine Fever Virus (ASFV) infection in porcine macrophages, demonstrating cross-species antiviral activity against a pathogen with no approved vaccine or treatment.^{[5, 8]} Jackman et al. (2022, Pathogens 12:1193) showed GML effectively inhibits ASFV, a devastating livestock pathogen. This extends GML's demonstrated activity from human viruses (HIV-1, Zika, YFV, mumps) to veterinary viruses, and positions GML as a GRAS alternative to antibiotics and chemical disinfectants in agricultural biosecurity. A separate study also confirmed GML and medium-chain fatty acids inhibit ASFV in feed matrices.

Caveats and open questions

What this paper doesn't settle

The exact molecular interaction between GML and the viral envelope remains uncharacterized — the paper does not establish whether GML inserts into the lipid bilayer, disrupts specific envelope protein conformations, or acts through another physical mechanism. The relationship between envelope maturation and GML sensitivity is an explicitly provisional hypothesis in the source paper, which states 'further studies are needed for confirmation.' The relative contribution of direct virucidal versus immunomodulatory mechanisms in vivo is entirely unknown. Reutericyclin's antiviral mechanism is inferred from structural analogy to GML, not independently dissected. Only CXCR4-tropic HIV-1 was tested; CCR5-tropic virus susceptibility — critical for sexual transmission modeling — is untested.

The honest skeptical read

This is entirely in vitro work using lab-adapted HIV-1 strain NL4.3, which is CXCR4-tropic (X4). The strains that dominate sexual transmission use the CCR5 coreceptor, not CXCR4 — meaning the paper's mechanistic story of coreceptor blockade has not been tested against the clinically relevant virus. The concentrations required (IC50 ~40 μg/ml) may not be achievable or maintainable at mucosal surfaces in vivo. Previous microbicide candidates that showed in vitro and even macaque-model promise — notably nonoxynol-9 — failed catastrophically in clinical trials, in some cases increasing HIV transmission by disrupting epithelial barriers. The 2009 Nature macaque study showed GML worked through immunomodulation, not direct virucidal activity, and the two mechanisms have not been tested together in a clinical setting.

Common misconception

Two widespread misconceptions deserve correction. First, 'virucidal' does not mean 'therapeutic' — GML has no effect once a cell is already infected, and it must be present at the exact moment of viral exposure. It is a prophylactic contact agent, not a treatment. Second, eating coconut oil or lauric-acid-rich foods will not provide systemic antiviral protection against HIV: GML must directly contact viral particles at mucosal surfaces, and dietary lauric acid is metabolized long before reaching relevant concentrations at infection sites. The evidence is for topical application, not dietary supplementation, as an antiviral strategy.